NCT06930989Completed
Primary Prevention Long-term Registry Study in OSA and Hypertension. Survival Analysis 2010-2022
Twin Threat of OSA and Hypertension on Mortality/CV-risk and Protective Effect by Positive Airway Pressure Treatment.
Source: ClinicalTrials.gov · Last updated 23 May 2025
Brief summary (registry, in English)
Hypertension and obstructive sleep apnea (OSA) are both common conditions that independently increase the risk cardiovascular disease including atrial fibrillation, ischemic heart disease, heart failure and stroke. OSA is also an independent promoter of hypertension development and poorly controlled hypertension is overrepresented in OSA. Finally, HT and OSA share many risk factors including obesity, and several lifestyle factors. Altogether, these links contribute to a high prevalence of patients with both disorders. The investigators suspect participants with HT and OSA are at even higher CV risk and may get their first CV event earlier in life. Comparison between HT and OSA participants vs HT alone, OSA alone or healthy controls has not previously been investigated in large studies. Thus, the investigators aim to investigate long-term risk of major cardiovascular events (MACE) or death comparing these groups in registry data between 2010-2022 in Sweden. The investigators will also investigate the protecting effect of positive airway pressure (PAP) on the OSA related CV risk increase and how many hours/night of PAP use is needed to get any protective effects.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 148467 (actual)
- First submitted
- 8 Apr 2025
- Start date
- 1 Jan 2025
- Primary completion date
- 8 Apr 2025
- Lead sponsor
- Vastra Gotaland Region
- Diseases
- High blood pressure
- NCT number
- NCT06930989
What you commit to
- Study type: Observational
- Participants enrolled: 148467
- From 1 Jan 2025 to the primary completion date, 8 Apr 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with manifest cardiovascular disease (stroke, ischemic heart disease, cardiac failure or atrial fibrillation at baseline).
- Patients with kidney failure at baseline.
- Patients with malignant cancer at baseline.
Other
- Subjects with missing data on any of the main variables in the fitted models.
Who the study is looking for
- Adult patients starting PAP treatment for OSA in the swedevox registry between 2010-2021 with and without hypertension. Randomly selected controls with and without hypertension from the general population.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Sahlgrenska University Hospital and Göteborg University Coordinator of this site? Confirm its status | Gothenburg | Sweden | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.